Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation"

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Ibrutinib and Venetoclax for First-Line Treatment of CLL

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The treatment of chronic lymphocytic leukemia (CLL) is in rapid transition, and during recent decades both combination chemotherapy and immunotherapy have been introduced. To evaluate the effects of this development, we identified all CLL patients registered in the nation-wide Danish Cancer Register between 1978 and 2013. We identified 10 455 CLL patients and 508 995 CLL-free control persons from the general population. Compared with the latter, the relative mortality rate between CLL patients and their controls decreased from 3.4 (95% CI 3.2-3.6) to 1.9 (95% CI 1.7-2.1) for patients diagnosed in 1978-1984 and 2006-2013, respectively. The improved survival corresponded to a decreasing risk of death from malignant hematological diseases, whereas the risk of death from infections was stable during the study period. These population-based data substantiate the improved survival for patients treated with chemo-immunotherapy demonstrated in clinical studies.

OriginalsprogEngelsk
TidsskriftBlood Cancer Journal
Vol/bind6
Udgave nummer11
Sider (fra-til)e499
ISSN2044-5385
DOI
StatusUdgivet - 11 nov. 2016

ID: 49896691